CBR1
Carbonyl reductase [NADPH] 1
Also known as: CBR, CBR1_HUMAN, SDR21C1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P16152
- Gene
- CBR1
- Ensembl
- ENSG00000159228
- Chromosome
- 21
- Canonical length
- 277 aa
- Protein class
- Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
The protein encoded by this gene belongs to the short-chain dehydrogenases/reductases (SDR) family, which function as NADPH-dependent oxidoreductases having wide specificity for carbonyl compounds, such as quinones, prostaglandins, and various xenobiotics. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Nov 2013]
Canonical amino-acid sequenceUniProt
277 residues, UniProt reviewed canonical sequence.
>P16152|CBR1
1 MSSGIHVALV TGGNKGIGLA IVRDLCRLFS GDVVLTARDV TRGQAAVQQL QAEGLSPRFH
61 QLDIDDLQSI RALRDFLRKE YGGLDVLVNN AGIAFKVADP TPFHIQAEVT MKTNFFGTRD
121 VCTELLPLIK PQGRVVNVSS IMSVRALKSC SPELQQKFRS ETITEEELVG LMNKFVEDTK
181 KGVHQKEGWP SSAYGVTKIG VTVLSRIHAR KLSEQRKGDK ILLNACCPGW VRTDMAGPKA
241 TKSPEEGAET PVYLALLPPD AEGPHGQFVS EKRVEQWLocalizationUniProt · AlphaFold · HPA
Whether an antibody against CBR1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.24
- Highest tissue expression
- 549 nTPM
Expression across tissuesHPA
Tissue
- duodenum: 549 nTPM
- choroid plexus: 379 nTPM
- small intestine: 326 nTPM
- liver: 236 nTPM
- spinal cord: 227 nTPM
- basal ganglia: 201 nTPM
Single-cell type
- enterocytes: 1,118 nCPM
- esophageal basal cells: 684 nCPM
- esophageal suprabasal cells: 458 nCPM
- suprabasal keratinocytes: 356 nCPM
- basal keratinocytes: 322 nCPM
- hepatocytes: 321 nCPM
Immune cell
- intermediate monocyte: 199 nTPM
- total PBMC: 162 nTPM
- non-classical monocyte: 158 nTPM
- classical monocyte: 134 nTPM
- myeloid DC: 110 nTPM
- naive CD4 T-cell: 103 nTPM
Brain region
- white matter: 356 nTPM
- choroid plexus: 249 nTPM
- basal ganglia: 226 nTPM
- cerebellum: 202 nTPM
- thalamus: 188 nTPM
- cerebral cortex: 182 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.53
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.09
- DepMap mean gene effect
- 0.15
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- epithelial cell differentiation
- glucocorticoid metabolic process
- positive regulation of reactive oxygen species metabolic process
- prostanoid biosynthetic process
- vitamin K metabolic process
- xenobiotic metabolic process
Molecular functions
- 15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity
- carbonyl reductase (NADPH) activity
- oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor
- oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
- S-nitrosoglutathione reductase (NADPH) activity
- 15-hydroxyprostaglandin dehydrogenase (NADP+) activity
- prostaglandin E2 9-reductase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of CBR1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads CBR1 as an antibody target. Whether an autoantibody or antibody against CBR1 could matter depends on whether native CBR1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
CBR1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label CBR1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...